Ascendis Pharma A (ASND) Other Non-Current Liabilities (2019 - 2026)

Ascendis Pharma A (ASND) has 8 years of Other Non-Current Liabilities data on file, last reported at $67.1 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities rose 67.6% year-over-year to $67.1 million; the trailing twelve-month figure through Mar 2026 stood at $67.1 million (up 67.6% YoY), and the FY2025 full-year result was $67.8 million, down 7.88% from the prior year.
• Other Non-Current Liabilities retreated to $67.1 million in Q1 2026, from $67.8 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $72.6 million in Q4 2024 to a low of $14.1 million in Q1 2022.
• A 5-year average of $39.2 million and a median of $36.6 million in 2023 frame the typical range for Other Non-Current Liabilities.
• Across the five-year window, Other Non-Current Liabilities fell 6.7% in 2025 and surged 67.6% in 2026, its largest moves.
• Tracing ASND's Other Non-Current Liabilities over 5 years: stood at $32.6 million in 2022, then soared by 35.75% to $44.3 million in 2023, then soared by 63.91% to $72.6 million in 2024, then decreased by 6.7% to $67.8 million in 2025, then dropped by 0.96% to $67.1 million in 2026.
• Business Quant data shows ASND's Other Non-Current Liabilities at $67.1 million in Q1 2026, $67.8 million in Q4 2025, and $56.5 million in Q3 2025.